Stock Analysis
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Taysha Gene Therapies, Inc. (TSHA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Taysha Gene Therapies, Inc. (TSHA) currently has an AIQ Score of 35/100, indicating a bearish setup. Quality is the strongest factor at 37/100. Momentum is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TSHA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $4.10 |
| AIQ Score | 35/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $1.67B |
| P/E Ratio (TTM) | -9.53 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.10 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.73 |
| Volume | 2.47M |
| 52-week range | $3.46-$7.30 |
| RSI 14 | 44.68 |
| 50-Day SMA | $4.49 |
| 200-Day SMA | $5.30 |
| Analyst Price Target | — |
| Next Earnings | Mar 3, 2027 |
TSHATaysha Gene Therapies, Inc.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum32
- Value—
- Quality37
- Risk resilience37
- Sentiment—
TSHA Stock Analysis Summary
Taysha Gene Therapies, Inc. (TSHA) currently has an AIQ Score of 35/100, indicating a bearish setup. Quality is the strongest factor at 37/100. Momentum is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, TSHA has AIQ Score of 35/100 with Quality base of 37/100 and fading Momentum at 32/100. Wait for component alignment before adding exposure.
Healthcare · -2.61% stock move · TSHA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TSHA Bullish or Bearish Right Now?
TSHA currently has a bearish overall setup. Quality is the strongest factor at 37/100, while Momentum is weakest at 32/100. The current evidence suggests a bearish setup.
- - No strong bullish evidence is available in the current snapshot.
- - Momentum is weak at 32/100.
- - Risk Resilience is weak at 37/100.
- - Price is -22.63% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (29 vs 9).
Current Consensus
TSHA's Technical Analysis Consensus is currently Sell, with 9 buy, 8 neutral, and 29 sell votes. TSHA's 14-day RSI is 44.68, which places the stock in a weaker momentum range. TSHA's beta is 1.73, indicating greater market sensitivity than the broad market.
What Changed in TSHA?
The largest recent change in TSHA is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the TSHA Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TSHA Decision Framework
Public evidence layers, setup checks, and risk context for Taysha Gene Therapies, Inc..
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Taysha Gene Therapies, Inc. has an AIQ Score of 35/100 in a Bearish regime. Quality is strongest at 37/100. Beta is 1.73, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TSHA is in a Bearish AIQ regime with score 35/100. |
| Signal Conflict | The primary conflict is that quality leads at 37/100 while momentum lags at 32/100. |
| Factor Evidence | Momentum 32/100 · Quality 37/100 · Risk 37/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 37/100.
Momentum is 32/100 and RSI (14) is 44.7.
TSHA is in a Bearish regime at 35/100.
Risk factor is 37/100 with beta 1.73 and annual volatility 70.69%.
Current conflict: quality leads at 37/100 while momentum lags at 32/100.
TSHA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TSHA Fundamentals
TSHA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TSHA Technical Analysis
TSHA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TSHA Stock Catalysts
Track TSHA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TSHA Dividend Analysis
TSHA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TSHA Financial Data
TSHA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TSHA Risk Analysis
TSHA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TSHA Stock News
TSHA stock news, market tone, recent headlines, and catalyst context.
TSHA vs Biotechnology Peers
Current peer cohort: TSHA · TVTX · TWST · TYRA · URGN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TSHA Current stock | 35/100 | — | 32/100 | 37/100 | 0.32 | 70.69% | Current |
| TVTX Travere Therapeutics, Inc. | 64/100 | 69/100 | 67/100 | 55/100 | 0.87 | 62.28% | TSHA vs TVTX |
| TWST Twist Bioscience Corporation | 64/100 | 58/100 | 84/100 | 32/100 | 1.94 | 84.18% | TSHA vs TWST |
| TYRA Tyra Biosciences, Inc. | 49/100 | — | 27/100 | 45/100 | 0.65 | 67.91% | TSHA vs TYRA |
| URGN UroGen Pharma Ltd. | 53/100 | 64/100 | 40/100 | 40/100 | 0.39 | 61.94% | TSHA vs URGN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for TSHA: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TSHA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TSHA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TSHA Stock FAQ
What is TSHA stock price today?
Taysha Gene Therapies, Inc.'s current stock price is $4.10. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TSHA bullish or bearish right now?
TSHA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TSHA's market cap?
TSHA's market cap is $1.67B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TSHA's current P/E ratio?
TSHA's current P/E ratio is -9.53 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TSHA's RSI?
TSHA's 14-day RSI is 44.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TSHA above its 50-day and 200-day moving averages?
TSHA is -8.73% from its 50-day SMA and -22.63% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TSHA's next earnings date?
TSHA's next earnings date is currently listed as Mar 3, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TSHA pay a dividend?
TSHA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.